Published in Mod Pathol on May 13, 2016
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified from reactive idiopathic hypereosinophilic syndrome. Haematologica (2017) 0.75
Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia. Leukemia (2017) 0.75
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) (1975) 9.01
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med (2014) 6.89
Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med (2014) 6.12
NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med (1982) 4.70
The idiopathic hypereosinophilic syndrome. Blood (1994) 4.65
European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica (2005) 4.34
Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med (2014) 3.75
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol (2009) 3.74
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2012) 3.43
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med (2015) 3.42
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol (2012) 2.78
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood (2015) 2.46
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia (2013) 2.11
MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood (2015) 1.52
Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood (2015) 1.38
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood (2014) 1.34
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood (2014) 1.10
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia (2013) 1.06
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res (2013) 1.04
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood (2015) 0.98
Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. Am J Hematol (2012) 0.98
A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood (1981) 0.94
CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia. J Hematol Oncol (2014) 0.91
World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Am J Hematol (2015) 0.88
KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance. Am J Hematol (2015) 0.86
Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. Oncotarget (2014) 0.85
Chronic eosinophilic leukaemia (CEL): a distinct myeloproliferative disease. Br J Haematol (1997) 0.84
Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome. Oncotarget (2015) 0.82
Chronic eosinophilic leukemia presenting with autoimmune hemolytic anemia and erythrophagocytosis by eosinophils. Am J Hematol (2006) 0.81
Eosinophilic leukemia: a myeloproliferative disorder distinct from the hypereosinophilic syndrome. Hematol Pathol (1991) 0.80
The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). Hematology Am Soc Hematol Educ Program (2015) 0.79
Isolated +15 in bone marrow: disease-associated or a benign finding? Leuk Res (2014) 0.79
Nuclear hypersegmentation of neutrophils, eosinophils, and basophils due to hydroxycarbamide (hydroxyurea). Blood (2014) 0.78
Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. Mod Pathol (2015) 0.78
Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy. Br J Haematol (2016) 0.76
Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. Mod Pathol (2015) 0.85
Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists. Mod Pathol (2014) 0.85
High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol (2014) 0.84
Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Mod Pathol (2016) 0.81
Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res (2014) 0.80
Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. Mod Pathol (2016) 0.79
A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. Mod Pathol (2016) 0.78
Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm. Cancer Genet (2015) 0.76
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer (2016) 0.75
Making a meal of multiple mutations (and other morphologic and molecular maladies) in myeloid malignancies II: Myeloproliferative neoplasms. Pathology (2016) 0.75
B-cells behaving badly II: A better basis to behold belligerence in aggressive B-cell lymphomas. Pathology (2016) 0.75
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified from reactive idiopathic hypereosinophilic syndrome. Haematologica (2017) 0.75
Making a meal of multiple mutations (and other morphologic and molecular maladies) in myeloid malignancies I: Acute myeloid leukemia. Pathology (2016) 0.75
Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Mod Pathol (2016) 0.75
B-cells behaving badly I: A better basis to behold belligerence in small B-cell lymphomas. Pathology (2016) 0.75
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBioMedicine (2017) 0.75
B-cells behaving badly II: A better basis to behold belligerence in aggressive B-cell lymphomas. Pathology (2016) 0.75
B-cells behaving badly I: A better basis to behold belligerence in small b-cell lymphomas. Pathology (2016) 0.75